FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912421341> ?p ?o ?g. }

• W2912421341 endingPage "411" @default.
• W2912421341 startingPage "411" @default.
• W2912421341 abstract "411 Background: FOLFIRINOX (FFX) is a standard therapy for unresectable/recurrent pancreatic cancer, but it is associated with a high frequency of severe adverse events, especially blood toxicity. Human pegylated granulocyte colony-stimulating factor (PEG-G-CSF) can reduce the outpatient frequency during outpatient chemotherapy. However, there are few reports on the effectiveness of PEG-G-CSF in preventing febrile neutropenia during FFX. We retrospectively investigated the usefulness of PEG-G-CSF in reducing the incidence of FN during FFX. Methods: From June 2014 to January 2017, 40 patients with unresectable pancreatic cancer received FFX (including modified FFX) at our hospital. Twenty-three patients were administered PEG-G-CSF as primary/secondary preventive therapy (G group) and 17 were not administered any G-CSF (NG group). Results: The median patient ages in the G and NG groups were 65 (range, 48-78) and 63 (range, 42-81) years, respectively, and the male to female ratios were 13:10 and 11:6, respectively. There were 13 and 10 patients, respectively, in the G group with performance statuses of 0 and 1 and 8 and 9 such patients, respectively, in the NG group. Seventeen and five patients in the G and NG groups, respectively, had metastatic disease and six and two patients, respectively, had locally advanced disease. The respective response rates (RRs) in the G and NG groups were 30% and 6% (p = 0.0608), and the respective disease control rates (DCRs) were 30% and 41% (p = 0.0407). The median progression-free survivals in the G and NG groups were 7.3 (95% confidence interval [CI], 3–9.4) and 4.5 (95% CI, 1.9–8.5) months, respectively (p = 0.173), and the respective overall survivals were 16.9 (95% CI, 10.2–NA) and 14.2 (95% CI, 7.8–20.5) months (p = 0.302). Conclusions: The DCR was significantly greater in the G group than in the NG group, and the RR tended to be greater in the G group than in the NG group. A high tumor shrinking effect of FFX with PEG-G-CSF indicated that it might be useful as a neoadjuvant chemotherapy. A prospective study is needed to examine first-line chemotherapy in unresectable/recurrent pancreatic cancer and neoadjuvant chemotherapy in borderline/locally advanced pancreatic cancer." @default.
• W2912421341 created "2019-02-21" @default.
• W2912421341 creator A5004543984 @default.
• W2912421341 creator A5004892486 @default.
• W2912421341 creator A5016494036 @default.
• W2912421341 creator A5019358201 @default.
• W2912421341 creator A5020464752 @default.
• W2912421341 creator A5024695820 @default.
• W2912421341 creator A5030403672 @default.
• W2912421341 creator A5032293640 @default.
• W2912421341 creator A5037147135 @default.
• W2912421341 creator A5038264481 @default.
• W2912421341 creator A5040116257 @default.
• W2912421341 creator A5046638834 @default.
• W2912421341 creator A5050624045 @default.
• W2912421341 creator A5051078028 @default.
• W2912421341 creator A5054288931 @default.
• W2912421341 creator A5075173113 @default.
• W2912421341 creator A5075563299 @default.
• W2912421341 creator A5079911973 @default.
• W2912421341 creator A5083990843 @default.
• W2912421341 creator A5087134875 @default.
• W2912421341 date "2019-02-01" @default.
• W2912421341 modified "2023-09-25" @default.
• W2912421341 title "Effect of FOLFIRINOX with PEG-G-CSF for unresectable/recurrent pancreatic cancer." @default.
• W2912421341 doi "https://doi.org/10.1200/jco.2019.37.4_suppl.411" @default.
• W2912421341 hasPublicationYear "2019" @default.
• W2912421341 type Work @default.
• W2912421341 sameAs 2912421341 @default.
• W2912421341 citedByCount "1" @default.
• W2912421341 countsByYear W29124213412023 @default.
• W2912421341 crossrefType "journal-article" @default.
• W2912421341 hasAuthorship W2912421341A5004543984 @default.
• W2912421341 hasAuthorship W2912421341A5004892486 @default.
• W2912421341 hasAuthorship W2912421341A5016494036 @default.
• W2912421341 hasAuthorship W2912421341A5019358201 @default.
• W2912421341 hasAuthorship W2912421341A5020464752 @default.
• W2912421341 hasAuthorship W2912421341A5024695820 @default.
• W2912421341 hasAuthorship W2912421341A5030403672 @default.
• W2912421341 hasAuthorship W2912421341A5032293640 @default.
• W2912421341 hasAuthorship W2912421341A5037147135 @default.
• W2912421341 hasAuthorship W2912421341A5038264481 @default.
• W2912421341 hasAuthorship W2912421341A5040116257 @default.
• W2912421341 hasAuthorship W2912421341A5046638834 @default.
• W2912421341 hasAuthorship W2912421341A5050624045 @default.
• W2912421341 hasAuthorship W2912421341A5051078028 @default.
• W2912421341 hasAuthorship W2912421341A5054288931 @default.
• W2912421341 hasAuthorship W2912421341A5075173113 @default.
• W2912421341 hasAuthorship W2912421341A5075563299 @default.
• W2912421341 hasAuthorship W2912421341A5079911973 @default.
• W2912421341 hasAuthorship W2912421341A5083990843 @default.
• W2912421341 hasAuthorship W2912421341A5087134875 @default.
• W2912421341 hasConcept C121608353 @default.
• W2912421341 hasConcept C126322002 @default.
• W2912421341 hasConcept C141071460 @default.
• W2912421341 hasConcept C197934379 @default.
• W2912421341 hasConcept C2776694085 @default.
• W2912421341 hasConcept C2777063308 @default.
• W2912421341 hasConcept C2777148230 @default.
• W2912421341 hasConcept C2777767877 @default.
• W2912421341 hasConcept C2778850193 @default.
• W2912421341 hasConcept C2779171977 @default.
• W2912421341 hasConcept C2780210213 @default.
• W2912421341 hasConcept C2780259306 @default.
• W2912421341 hasConcept C526805850 @default.
• W2912421341 hasConcept C71924100 @default.
• W2912421341 hasConcept C90924648 @default.
• W2912421341 hasConceptScore W2912421341C121608353 @default.
• W2912421341 hasConceptScore W2912421341C126322002 @default.
• W2912421341 hasConceptScore W2912421341C141071460 @default.
• W2912421341 hasConceptScore W2912421341C197934379 @default.
• W2912421341 hasConceptScore W2912421341C2776694085 @default.
• W2912421341 hasConceptScore W2912421341C2777063308 @default.
• W2912421341 hasConceptScore W2912421341C2777148230 @default.
• W2912421341 hasConceptScore W2912421341C2777767877 @default.
• W2912421341 hasConceptScore W2912421341C2778850193 @default.
• W2912421341 hasConceptScore W2912421341C2779171977 @default.
• W2912421341 hasConceptScore W2912421341C2780210213 @default.
• W2912421341 hasConceptScore W2912421341C2780259306 @default.
• W2912421341 hasConceptScore W2912421341C526805850 @default.
• W2912421341 hasConceptScore W2912421341C71924100 @default.
• W2912421341 hasConceptScore W2912421341C90924648 @default.
• W2912421341 hasIssue "4_suppl" @default.
• W2912421341 hasLocation W29124213411 @default.
• W2912421341 hasOpenAccess W2912421341 @default.
• W2912421341 hasPrimaryLocation W29124213411 @default.
• W2912421341 hasRelatedWork W136411592 @default.
• W2912421341 hasRelatedWork W2032853726 @default.
• W2912421341 hasRelatedWork W2048644178 @default.
• W2912421341 hasRelatedWork W2051360772 @default.
• W2912421341 hasRelatedWork W2053128632 @default.
• W2912421341 hasRelatedWork W2158561707 @default.
• W2912421341 hasRelatedWork W2210770651 @default.
• W2912421341 hasRelatedWork W2367469818 @default.
• W2912421341 hasRelatedWork W2912421341 @default.
• W2912421341 hasRelatedWork W4250026301 @default.
• W2912421341 hasVolume "37" @default.
• W2912421341 isParatext "false" @default.

• next